Proscia
AI-powered pathology for precision medicine
Proscia is a digital pathology company offering the Concentriq platform, which provides AI-powered virtual staining and integrates with molecular tests and pathology reports to enhance diagnostic capabilities.
How We Help
Problem Statement
Proscia addresses the challenges in traditional pathology by providing a digital pathology platform that improves diagnostic efficiency and accuracy through AI-powered virtual staining and integration with molecular and pathology data.
Core Technology
The Concentriq platform for digital pathology, including an AI-powered virtual staining capability that generates H&E, IHC, and special stains on-demand. It integrates with molecular tests and pathology reports.
Key Differentiators
OEM agreement with Siemens Healthineers for integration into Siemens Enterprise Imaging for the global digital pathology market; Distribution partnership with Agilent Technologies for digital pathology solutions; AI-powered virtual staining capability powered by Pictor Labs technology
Clinical Focus
Pathology
Company Info
- Business Model
- B2B
- Total Funding
- 130,000,000
- Website
- proscia.com/
Categories
Technologies
Clinical & IP
Clinical Validation
FDA 510(k) cleared (K230839, Feb 2024); multi-site clinical study showing -0.1% major discordance vs. glass slides; 98% accuracy in skin biopsy classification; largest AI validation study in pathology
MedStartr Index Score
?What do you think of Proscia?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.